Sanofi-Aventis to cut hundreds of US sales reps

Share this article:

Sanofi-Aventis announced plans to cut 10% or less of its 6,500 US sales reps. Specific numbers are not yet available, as the company attempts to shuffle some of the redundant positions to other areas of the company, according to Marc Greene, a Sanofi spokesman. 

The announcement follows the commencement of Chris Viehbacher's tenure as Sanofi's CEO, which began on Dec. 1. Viehbacher, a PhRMA board member and previously GlaxoSmithKline's North America executive director and president, succeeds Gerard Le Fur.

Sanofi-Aventis's announcement coheres with many other consolidations and layoffs across the industry this year. Company-wide cost-cutting measures, like Wyeth's “Project Impact” and Novartis's “Customer Centric Initiative,” as well as other reductions of staff elsewhere, have become a common occurrence of late. A more comprehensive listing can be found here.

Share this article:

Email Newsletters

More in News

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.

GSK second-quarter sales disappoint

GSK second-quarter sales disappoint

Executives urge analysts to focus on the company's long-term potential.

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union